T2 Biosystems Reports Granting of Inducement Award
January 29 2021 - 4:05PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the
rapid detection of sepsis-causing pathogens, announced today that
it issued an inducement award to Dr. Aparna Ahuja, the Company’s
recently appointed Chief Medical Officer, in accordance with the
terms of Dr. Ahuja’s employment offer letter.
The award was made on January 5, 2021 under T2 Biosystems’
Inducement Award Plan (the "Inducement Plan"), which was adopted
March 1, 2018 (as amended to date) and provides for the granting of
equity awards to new employees of T2 Biosystems. The inducement
award consists of restricted stock units (“RSUs”) covering 460,992
shares of the Company’s common stock. Subject to Dr. Ahuja’s
continued service to the Company, one third of the RSUs shall vest
on each of the first two anniversaries of the grant date and the
remainder shall vest on the third anniversary of the grant date.
The award is subject to the terms and conditions of the Inducement
Plan and the terms and conditions of an applicable award agreement
covering the grant. The award was approved by the T2
Biosystems’ board of directors and was granted as an inducement
material to the new employee entering into employment with T2
Biosystems in accordance with Nasdaq Marketplace Rule
5635(c)(4).
About T2 Biosystems:T2 Biosystems, a leader in
the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2ResistanceTM Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2CaurisTM Panel, and T2Lyme TM
Panel, as well as additional products for the detection of
bacterial and fungal pathogens and associated antimicrobial
resistance markers, and biothreat pathogens.
Media Contact:Gina Kent, Vault
Communicationsgkent@vaultcommunications.com 610-455-2763
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024